|Bid||115.70 x 1000|
|Ask||115.71 x 800|
|Day's Range||114.52 - 115.83|
|52 Week Range||79.11 - 118.28|
|Beta (5Y Monthly)||0.80|
|PE Ratio (TTM)||39.71|
|Earnings Date||Jul. 29, 2021 - Aug. 02, 2021|
|Forward Dividend & Yield||5.20 (4.51%)|
|Ex-Dividend Date||Apr. 14, 2021|
|1y Target Est||124.08|
In the latest trading session, AbbVie (ABBV) closed at $115.40, marking a -0.02% move from the previous day.
(Bloomberg) -- I-Mab is seeking a partner to jointly develop a cancer drug in the U.S. and Europe as the Chinese firm aims to replicate the success of last year’s $2.9 billion deal with AbbVie Inc., according to people familiar with the matter.The Shanghai-based drug developer is working with advisers and is in talks with several global pharmaceutical companies over a potential deal for its Uliledlimab, or TJD5, treatment that could be worth a few billion dollars, the people said, asking not to
If you're retired or approaching retirement, you'll definitely want to consider including high-quality dividend stocks in your portfolio. Here are three top dividend stocks that are great picks to buy in June. Arguably the most important thing to know about AbbVie's (NYSE: ABBV) pedigree is that it's a Dividend Aristocrat.